SAFETY PROFILE OF TASOCITINIB (CP-690,550)-BASED CNI-FREE REGIMENS IN DE NOVO KIDNEY TRANSPLANT PATIENTS IN A DOSE/EXPOSURE-FINDING PHASE 2B STUDY: RESULTS OF A 6-MONTH INTERIM ANALYSIS | Publicación